StockNews.AI
MRK
StockNews.AI
67 days

FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent

1. FDA approves KEYTRUDA for advanced head and neck cancer treatment. 2. This expands MRK's oncology portfolio significantly.

2m saved
Insight
Article

FAQ

Why Very Bullish?

FDA approvals often lead to immediate revenue boosts; past approvals have driven MRK's stock positively, such as with KEYTRUDA in lung cancer.

How important is it?

The approval of KEYTRUDA directly enhances MRK's growth potential, impacting investor confidence and stock valuation.

Why Long Term?

New approvals can lead to sustained revenue growth over years as products are adopted and established in treatment protocols.

Related Companies

BMYAMGNREGN
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, con.

Related News